tirzepatide surmount-1 weight loss percent nejm 2022 In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, was superior to semaglutide in reducing body and waist circumference. Full trial results and Research Summary Zepbound Clinical Trial Results: SURMOUNT-1

These receptors play a key role in managing appetite and insulin production

Tirzepatide is a dual agonist that mimics the actions of GLP-1 and GIP hormones, leading to increased insulin secretion and reduced appetite

It suppresses appetite broadly, leaving the job of protecting muscle to you

Side effects and safety 6 Wegovy side effects you need to be aware of Wegovy and Wegovy HD (semaglutide) are GLP-1 weight-loss medicines that can be associated with common stomach side effects like nausea, vomiting and diarrhea

If you have any questions or inquiries about our products, please feel free to contact us and we will respond as soon as possible